Steven R. Olsen

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

DJ Slamon, W. Eiermann, Nicholas J. Robert et al. · Cancer Research · 2009 · 554 citations

Medicine, Oncology, Pharmacology +17

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Stephen E. Jones, John K. Erban, Beth Overmoyer et al. · Journal of Clinical Oncology · 2005 · 547 citations · Full text

Medicine, Oncology, Pharmacology +14

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li et al. · Clinical Cancer Research · 2013 · 199 citations

Medicine, Oncology, Pharmacology +17

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis et al. · Breast Cancer Research and Treatment · 2009 · 160 citations

Medicine, Oncology, Breast Oncology +14